Gilead riporta un'efficacia del 96% nella prevenzione dell'HIV con il nuovo farmaco lenacapavir
ha condiviso i risultati dello studio di
Fase 3 PURPOSE 2, che mostrano l'efficacia di lenacapavir, un inibitore del
capside dell'HIV-1 ... |
Italiano — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.